- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
1. Financial Highlights:
Hikal Ltd reported FY25 revenue of Rs 1,860 Cr, up 4% YoY, with EBITDA increasing 23% to Rs 328 Cr, driving margin expansion by 270 bps to 17.7%. Q4 revenue jumped 23% QoQ to Rs 552 Cr, with EBITDA margin rising to 22.4%. Net profit rose 31% YoY to Rs 91.7 Cr, supported by improved product mix and efficiencies. Net Debt/Equity improved to 0.59x from 0.67x, reflecting better cash flows and lower debt. Pharma grew 20% in Q4, while crop protection had 30% QoQ revenue growth despite margin pressure.
2. Strategic Initiatives & Growth Drivers:
Hikal is boosting global reach with a new R&D center and sustainability-driven capacity expansions including co-generation plants. The pharmaceutical CDMO segment is gaining traction with a strong project pipeline and regulatory approvals across EU, Japan, and Australia. Crop protection focuses on operational efficiency amid industry shifts, while animal health advances toward commercialization.
3. Business Developments:
Validation of 8 animal health products completed, alongside multiple successful audits. Acquisitions of manufacturing sites in Panoli and Bangalore enhance scale and integration. A key 10-year multi-product contract in animal health solidifies future growth prospects.
4. Market Position & Competitive Advantage:
Hikal’s diversified portfolio spanning pharma, crop protection, and specialty chemicals, combined with global regulatory approvals and integrated solutions, provide competitive edges. Scale and operational excellence are driving margin gains even amid macro challenges.
5. Investor Implications:
Strong innovation focus and expanding pipelines support positive growth potential. Improved financials reduce risk, though crop protection market dynamics and geopolitical factors warrant monitoring. Animal health commercialization and CDMO momentum add upside, with execution risks around supply chain volatility to watch.